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Abstract
Background: Nano-scaled cerium oxide (nCeO2) is used in a variety of applications, including use as a fuel additive,
catalyst, and polishing agent, yet potential adverse health effects associated with nCeO2 exposure remain incompletely
understood. Given the increasing utility and demand for engineered nanomaterials (ENMs) such as nCeO2, “safety-by-
design” approaches are currently being sought, meaning that the physicochemical properties (e.g., size and surface
chemistry) of the ENMs are altered in an effort to maximize functionality while minimizing potential toxicity. In vivo
studies have shown in a rat model that inhaled nCeO2 deposited deep in the lung and induced fibrosis. However, little
is known about how the physicochemical properties of nCeO2, or the coating of the particles with a material such as
amorphous silica (aSiO2), may affect the bio-activity of these particles. Thus, we hypothesized that the physicochemical
properties of nCeO2 may explain its potential to induce fibrogenesis, and that a nano-thin aSiO2 coating on nCeO2 may
counteract that effect.
Results: Primary normal human lung fibroblasts were treated at occupationally relevant doses with nCeO2 that was
either left uncoated or was coated with aSiO2 (amsCeO2). Subsequently, fibroblasts were analyzed for known hallmarks
of fibrogenesis, including cell proliferation and collagen production, as well as the formation of fibroblastic nodules.
The results of this study are consistent with this hypothesis, as we found that nCeO2 directly induced significant
production of collagen I and increased cell proliferation in vitro, while amsCeO2 did not. Furthermore, treatment of
fibroblasts with nCeO2, but not amsCeO2, significantly induced the formation of fibroblastic nodules, a clear indicator of
fibrogenicity. Such in vitro data is consistent with recent in vivo observations using the same nCeO2 nanoparticles and
relevant doses. This effect appeared to be mediated through TGFβ signaling since chemical inhibition of the TGFβ
receptor abolished these responses.
Conclusions: These results indicate that differences in the physicochemical properties of nCeO2 may alter the
fibrogenicity of this material, thus highlighting the potential benefits of “safety-by-design” strategies. In addition, this
study provides an efficient in vitro method for testing the fibrogenicity of ENMs that strongly correlates with in vivo
findings.
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Background
Cerium, of the lanthanide metal group, is considered a rare
earth metal. Rare earth metals have been reported to in-
duce pneumoconiosis upon occupational exposure, with
cerium found to persist in the alveoli and interstitial tissue
for decades even after exposure has ceased [1]. Indeed,
even the term “cerium pneumoconiosis” has been coined
due to the increasing prevalence of such disorders [2, 3].
Use of cerium oxide nanoparticles (nCeO2) has been
steadily increasing across many industries, as it is an effi-
cient polishing agent for glass, mirrors, and ophthalmic
lenses. In addition, it has been utilized as a diesel fuel cata-
lyst to aid in emission reduction, which subsequently leads
to its release in the particulate phase of exhaust [4, 5].
Other uses of nCeO2 in consumer goods are also in devel-
opment, including use as an additive in cosmetics and sun-
screens based on its UV absorption properties, and within
the pharmaceutical industry. Thus, human exposure is in-
evitable in environmental, consumer, and occupational set-
tings, with inhalation being the primary route of exposure.
Unfortunately, data is somewhat limited regarding human
exposure concentrations to nCeO2 in either occupational or
environmental settings. However, several individual case
studies of movie projectionists and photoengravers with
regular exposure to nCeO2 have noted the bio-persistence
of these particles following occupational exposures, with as-
sociated lung disease [6, 7]. Considering the increased de-
mand and use of this material, these reports highlight the
need to fully characterize potential exposure-induced health
effects associated with nCeO2 use.
Consistent with this notion, several studies have been
conducted in an effort to better understand nCeO2-in-
duced effects, with a focus on animal models of disease.
These reports have noted the presence of nCeO2-induced
pulmonary inflammation, cardiovascular dysfunction, and fi-
brosis, as well as the bio-accumulation of nCeO2, in agree-
ment with the observed effects reported in human case
studies [8–14]. Fibrosis is characterized by the excessive pro-
duction of extracellular matrix (ECM) components around
damaged lung tissue, which accumulate as the typical
wound healing response mediated by fibroblasts aberrantly
persists [15]. Under normal circumstances, following inflam-
mation or injury, fibroblasts within the lung interstitium
produce ECM proteins, such as collagen and fibronectin, in
an effort to repair the damaged connective tissue. However,
if left unchecked, fibrotic scarring can occur. Unfortunately,
very few, if any, therapeutic strategies for the management
of fibrosis currently exist, underlying the importance of de-
vising strategies to limit the chances of developing fibrosis
in occupational, consumer, and environmental settings.
Given the increasing utility and demand for engi-
neered nanomaterials (ENMs) such as nCeO2, “safety-
by-design” approaches are currently being sought in an
effort to maximize the functionality of ENMs while
minimizing their potential toxicity and adverse health ef-
fects. One such strategy is the use of surface coatings, such
as a nano-thin amorphous silica (aSiO2) coating, that would
provide a biologically inert shell while retaining the desired
core material properties when possible [16]. Recent studies
using nCeO2 coated with aSiO2 (amsCeO2) have suggested
that this approach may prove fruitful, as the coated version
of nCeO2 was able to substantially reduce nCeO2-induced
pulmonary inflammation, cytotoxicity, phospholipidosis,
and fibrosis following acute exposure in rats [9, 17].
While these studies provide critical insight into the
utility of this approach for designing safer ENMs, they
were completed primarily using in vivo testing models.
Given the high number of ENMs in development for
countless uses, recently there has been a stronger initia-
tive for more comprehensive in vitro models that would
allow for more cost- and time-effective screening tools
to identify potential toxicities and hazards associated
with the use of these ENMs. Consistently, in the current
report we sought to validate the reported in vivo findings
that a nano-thin coating of aSiO2 can limit the fibrogeni-
city of nCeO2 [9, 17] using an in vitro model consisting
of primary normal human lung fibroblast (NHLF) cell
cultures. Employing the same nCeO2 nanoparticles created
using the Harvard Versatile Engineered Nanomaterial Gen-
eration System (VENGES), herein we report that nCeO2
can directly stimulate NHLFs, inducing both proliferation
and excessive collagen production, both of which are clas-
sic hallmarks of fibrogenesis. Furthermore, exposure to
nCeO2 significantly induced the formation of fibrotic nod-
ules in cultured NHLFs. In clinical fibrosis, the presence
and number of such fibrotic foci is one of the most reliable
indicators of a poor prognosis [18–20]. As anticipated, the
nano-thin aSiO2 coating limited the fibrogenicity of nCeO2,
significantly decreasing the extent of nCeO2-induced fibro-
blast proliferation, collagen production, and nodule forma-
tion, to levels resembling non-treated control cultures.
Collectively these results further validate “safety-by-design”
strategies for formulating ENMs and offer the details of a
reliable in vitro model to analyze fibrogenicity that mimics
results observed in vivo.
Results
Preparation and characterization of particle liquid
suspensions for cellular studies
The nano-scaled cerium oxide (nCeO2), amorphous silica-
coated nCeO2 (amsCeO2), and the amorphous silica (aSiO2)
used in these studies were all generated using the Harvard
VENGES method. The aSiO2 was utilized in these studies
as a control particle, since this is the particle with which the
nCeO2 was encapsulated to create the amsCeO2 nanoparti-
cle. In order to further validate our in vitro model as it re-
lates to in vivo observations, we also included the use of an
additional uncoated nCeO2 that was not created using the
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VENGES system, but rather, was purchased commercially
from Sigma-Aldrich (denoted as Sigma in the figures) and
was tested previously in a rat model in which it was found
to induce fibrosis [10, 12]. Single-walled carbon nanotubes
(SWCNTs) were also used as a positive control based on
their previously reported fibrogenicity [21]. Table 1 summa-
rizes particle characterization data in both powder form and
in liquid suspension. Previously published transmission and
scanning electron microscopic images of the VENGES
nCeO2 and amsCeO2 samples collected in situ illustrate the
fractal structure of the agglomerates formed by the flame
synthesis method [17]. X-ray diffraction (XRD)-determined
crystal size of uncoated nCeO2 (17.3 nm) was slightly
smaller than that of amsCeO2 (21 nm). The specific surface
area (SSA) of nCeO2 was 61 m
2/g and the SSA of amsCeO2
was 50 m2/g, corresponding to an equivalent diameter of
12.8 nm and 19.2 nm, respectively. Differences between the
nCeO2 and amsCeO2 Brunauer–Emmett–Teller (BET)-
equivalent diameter are more pronounced than crystal sizes
due to the aSiO2 encapsulation, which is not accounted for
when measuring the crystal size.
Both the intensity- and volume-weighted hydrodynamic
diameter (dH), as well as the zeta potential of nCeO2, ams-
CeO2, and aSiO2 dispersed in sterilized deionized water
(DI H2O) and complete fibroblast growth media (FGM)
are summarized in Table 2. The zeta-potentials measured
for both aSiO2 and amsCeO2 dispersed in DI H2O were
strongly negative and significantly different from the
strongly positive zeta potential measured for nCeO2. All
three particles exhibited similar zeta potential values
around −12 mV when dispersed in FGM. Agglomerate di-
ameters as measured via dynamic light scattering (DLS)
were stable over the course of 24 h (data not shown). The
intensity-weighted dH for nCeO2 was 229.7 nm, while that
of amsCeO2 was 288.3 nm when the particles were sus-
pended in FGM. The polydispersity of both particles were
below 0.5, which is indicative of distribution of monodis-
persed particles. Additionally, the volumetric centrifuga-
tion method (VCM)-measured effective density of nCeO2
was 1.65 g/cm3, whereas that of amsCeO2 was 1.54 g/cm
3
when suspended in FGM.
Both the hydrodynamic diameter and the effective dens-
ity of these formed agglomerates can greatly affect the fate
and transport of the particles in vitro, in addition to defin-
ing settling rates, with significant implications for the dose
of particles actually delivered to cells over the course of
the in vitro toxicity assay. Thus, the delivered dose of
nanoparticles may not always equal the administered dose
[22–24]. In an effort to calculate the delivered-to-cell dose
of nCeO2, amsCeO2, and aSiO2, we employed the recently
developed Harvard in vitro dosimetry method [22], which
determines the fraction of the administered particles that
is deposited onto the cells in the bottom of the well as a
function of time (Table 3 and Fig. 1). As anticipated, the
nanoparticles did not behave exactly the same in the
FGM, with the nCeO2 settling at a slower rate than both
the amsCeO2 and aSiO2. While the amsCeO2 and aSiO2
achieved nearly 100 % deposition of the administered dose
by approximately 24 h, roughly 70 % of the administered
dose of nCeO2 was delivered to the cells over the
same time frame. nCeO2 did not reach the same level
of deposition as amsCeO2 or aSiO2 until at least 40 h
post-treatment. Based on these results, the analyses
reported herein were carried out 48 h post-exposure
to the nanoparticles to allow for complete deposition
of all particles.
Interestingly, the observed fibrogenic effects of nCeO2
following a 24 h exposure did reveal a similar trend as
the results presented herein that were obtained at the
48 h timepoint (data not shown). Although these results
did not reach statistical significance at 24 h post-
treatment, these findings highlight the increased fibro-
genic potential of the nCeO2 compared to the amsCeO2,
since there was roughly 30 % less deposition of the
nCeO2 at that time.
nCeO2 induces proliferation and collagen I expression in
fibroblasts
As previously mentioned, nCeO2 is known to accumulate
in the lungs in both humans and in animal models, and has
been found in the pulmonary interstitium long after expos-
ure has ceased [1, 6, 10]. This would suggest that nCeO2
would directly contact resident lung cell types, including fi-
broblasts. In an effort to determine whether nCeO2 directly
stimulates fibroblasts, we measured two hallmarks of fibro-
sis, cell proliferation and collagen production. Primary
Table 1 Characterization of the engineered nanoparticles
Nanomaterial Manufacturer Manufacturing process Theoretical aSiO2 (wt%) TCT (nm) dXRD (nm) dBET (nm) SSA (m
2/g)
nCeO2 Harvard University VENGES FSP 0 0 17.3 12.8 61
amsCeO2 Harvard University VENGES FSP 20 3 21 19.2 50
aSiO2 Harvard University VENGES FSP 100 n/d n/d 14 195
Sigma CeO2 Sigma-Aldrich n/d 0 n/d n/d 20 n/d
SWCNT CNI Houston HipCo 0 n/d n/d n/d 400 – 1200
Abbreviations: nCeO2 uncoated nCeO2, amsCeO2 amorphous SiO2-coated nCeO2, aSiO2 amorphous SiO2, n/d measurement not determined or data not available,
VENGES FSP versatile engineered nanomaterial generation system flame spray pyrolysis, HipCo high pressure CO disproportionation, TCT theoretical coating
thickness, dXRD x-ray diffraction calculated diameter, dBET Brunauer–Emmett–Teller calculated primary particle diameter, SSA specific surface area
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human fibroblasts were treated with a low dose, 0.006 μg/
cm2, as well as a high dose, 0.2 μg/cm2, which correspond
to the physiologically relevant doses that induced pulmon-
ary fibrosis in a rat model [10, 12]. In these in vivo studies,
the lowest dose of nCeO2 tested was 0.15 mg/kg body
weight. With an average weight of approximately 200 g
per rat as noted in the report, this dose translates to ap-
proximately 30 μg per animal. Based on the rat lung sur-
face area of 4000 cm2, this corresponds to a dose of
approximately 0.0075 μg/cm2, which was sufficient to in-
duce fibrosis at 84 days post-treatment. Using the same
calculations, the 3.5 mg/kg dose corresponds to approxi-
mately 0.2 μg/cm2, and this dose induced fibrosis 28 days
post-treatment [10, 12].
Following treatment with both the low and high doses,
cell proliferation was analyzed via nuclear stain and subse-
quent quantitation, which revealed that nCeO2 significantly
increased NHLF cell proliferation compared to non-treated
cells (Fig. 2). In contrast, amsCeO2 did not induce cell pro-
liferation at either dose, similar to the aSiO2 control, and
treatment with the amsCeO2 resulted in proliferation levels
that were significantly lower than the nCeO2 (Fig. 2). As
mentioned, in order to further validate our in vitro model
as it relates to in vivo observations, we also included the
use of an additional uncoated nCeO2, denoted as Sigma in
the figures, which also induced cell proliferation at both
doses tested, similar to the uncoated nCeO2 obtained using
the VENGES method.
Previous studies from our group have demonstrated that
SWCNTs are directly fibrogenic to fibroblast cells, indu-
cing cell proliferation as well as collagen production [21].
Thus, these particles were used as a positive control in the
studies reported herein. As expected, SWCNTs also in-
duced cell proliferation at levels similar to both uncoated
nCeO2 particles (Fig. 2). Similarly, the known fibrosis-
inducing cytokine transforming growth factor beta (TGFβ)
was used as a positive control and, as anticipated, invoked
a significant level of proliferation in these cells.
As discussed, fibrosis is associated with the activation of
fibroblast cells that stimulates the release and accumulation
of extracellular matrix proteins such as collagen. Hence,
collagen production was measured via Western blot ana-
lysis, as well as fluorescent microscopy, to determine
whether nCeO2 can induce the release of collagen directly
from fibroblast cells. As demonstrated in Fig. 3, we ob-
served a significant increase in collagen production in re-
sponse to both uncoated nCeO2 particles, as well as both
positive controls, SWCNT and TGFβ, compared to non-
treated cells. This effect was not observed in cells that had
been treated with amsCeO2. Furthermore, fibroblast cells
treated with 0.2 μg/cm2 of nCeO2, as well as the Sigma
CeO2, SWCNTs, and TGFβ, demonstrated increased ex-
pression of alpha-smooth muscle actin (α-SMA), which in-
dicates the activation and subsequent transformation of
fibroblasts into myofibroblasts (Fig. 3c), the main source of
collagen production during wound healing and fibrotic
Table 2 Properties of ENM dispersions in DI H2O and fibroblast growth medium
Nanomaterial Media Intensity-weighted dH (nm) PdI Volume-weighted dH (nm) ζ (mV) σ (mS/cm) ρagg (g/cm
3)
nCeO2 DI H2O 262.5 ± 28.56 0.398 ± 0.03 n/d 47.3 ± 6.22 0.0051 ± 0.489 n/d
FGM 229.7 ± 29.86 0.451 ± 0.11 187.79 ± 16.9 −12.6 ± 2.83 10.7 ± 0.306 1.65
amsCeO2 DI H2O 222.1 ± 8.86 0.249 ± 0.03 n/d −50.3 ± 2.00 0.0031 ± 6.08e-5 n/d
FGM 288.3 ± 5.43 0.354 ± 0.02 278.65 ± 11.8 −13.6 ± 0.92 8.00 ± 0.552 1.541
aSiO2 DI H2O 132.1 ± 4.45 0.190 ± 0.004 n/d −36.4 ± 3.81 0.0026 ± 1.57e-4 n/d
FGM 478.9 ± 35.31 0.437 ± 0.05 685.58 ± 263.9 −11.2 ± 2.18 13.0 ± 1.73 1.075
Abbreviations: n/d measurement not determined, dH hydrodynamic diameter, PdI polydispersity index, ζ zeta potential, σ specific conductance, ρagg effective
density. Values represent the mean (± SD) of a triplicate reading. Footnote: the average diameters obtained from DLS characterization are derived from the
intensity-weighted distributions based on the intensity of light scattered by the particle
Table 3 Relevant in vitro dose (RID) functions for nCeO2, amsCeO2, and aSiO2 nanoparticles when dispersed in FGM
Nanomaterial M N SA RIDM RIDN RIDSA
nCeO2 Low dose 0.01 2.08E-09 3.63E-16 0.01 1.08E-16 1.88E-23
nCeO2 High dose 0.40 4.25E-01 4.53E-01 0.36 2.20E-08 2.35E-08
amsCeO2 Low dose 0.01 6.82E-10 3.90E-17 0.01 5.88E-17 3.37E-24
amsCeO2 High dose 0.40 3.10E-01 2.41E-01 0.39 2.68E-08 2.08E-08
aSiO2 Low dose 0.01 6.56E-11 9.69E-05 0.01 3.11E-18 4.60E-12
aSiO2 High dose 0.40 1.10E + 00 1.62E + 06 0.39 5.20E-08 7.68E-02
Delivered dose values based on delivered ENM mass (M), delivered particle number (N), and delivered surface area (SA) for either a high (0.57 μg/mL, equivalent
to 0.2 μg/cm2 for this study) or low (0.017 μg/mL, 0.006 μg/cm2) dose
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events. In contrast, the amsCeO2, as well as the aSiO2
alone, expressed α-SMA at levels similar to the non-treated
cells. Taken together with the cell proliferation data, these
results demonstrate that the aSiO2 encapsulation of nCeO2
is capable of attenuating the fibrogenic nature of the nCeO2
as measured in vitro, in agreement with in vivo reports [9].
nCeO2, but not amsCeO2, induces the formation of
fibroblastic nodules
We next utilized a fibroblastic nodule assay to further
analyze the fibrogenicity of nCeO2, as well as the effect that
the encapsulation of this particle with aSiO2 has on this
process. A key pathological characteristic of fibrosis is the
formation of fibrotic foci composed of fibroblasts, myofi-
broblasts, and accumulated collagen [18, 25, 26]. Consist-
ently, formation of these foci in vitro is recognized as a
useful method to assess the fibrogenic potential of nanoma-
terials. Primary human lung fibroblasts were plated on cov-
erslips that had been coated with poly-L-lysine and
subsequently treated with nanoparticles, as indicated, and
nodule formation was assessed. As anticipated, we observed
that both of the uncoated forms of nCeO2 directly and sig-
nificantly induced the formation of fibroblastic nodules in
these cells in a dose dependent manner, as did both positive
controls (Fig. 4). The amsCeO2 did not induce extensive
formation of fibroblastic foci, stimulating the formation of
only a few foci per well, consistent with numbers observed
in the non-treated cell cultures, and significantly less than
nCeO2. In addition, confocal microscopy z-stack analysis
demonstrated that the fibrotic nodule clusters formed in re-
sponse to nCeO2 and TGFβ had an increased thickness as
compared to the untreated monolayer of NHLFs, indicating
the formation of multi-layer nodules (Fig. 4c).
Further analysis of the fibrotic nodules using enhanced
darkfield imaging revealed that the nCeO2 localizes at the
site of nodule formation (Fig. 5). Consistently, SWCNTs
also localized with the resulting fibrotic foci. Given that
nCeO2 has been shown to accumulate in the lungs follow-
ing exposure [1, 6, 10, 27–29], this data would suggest that
the formation of nodules may occur, at least in part, due to
the accumulation of aggregated nanoparticles on the fibro-
blast cells that then respond to the foreign material in an
aberrant manner.
The fibrogenic effect of nCeO2 is mediated by TGFβ
signaling
Finally, we sought to determine whether TGFβ signaling
was the mechanism by which nCeO2 was inducing
stimulation of the fibroblast cells, since this mediator
Fig. 1 Fraction of deposited nCeO2, amsCeO2, and aSiO2 particles over
a 48 h exposure, using fibroblasts cultured in 24-well tissue culture
plates in fibroblast growth medium. The Harvard in vitro dosimetry
method was used to determine the fraction of nanoparticle delivered
to cells as a function of time. Uncoated nCeO2 settled slower than both
amsCeO2 and aSiO2, with all nanoparticles achieving approximately
90 % deposition by 40 h post-administration to cells
Fig. 2 nCeO2 directly induces proliferation of NHLFs, while amsCeO2 does not. Quantitation of DAPI stained nuclei of NHLFs that had been treated for
48 h was used to determine cell counts at the indicated doses and treatments. nCeO2 induced a significant increase in cell proliferation at both
0.006 μg/cm2 (a) and 0.2 μg/cm2 (b) compared to non-treated cells as well as those treated with amsCeO2. SWCNTs and TGFβ (1 ng/mL) were used as
positive controls and also significantly increased proliferation of the fibroblast cells. Statistical significance is indicated as *p < 0.05, **p < 0.01,
and ***p < 0.001 compared to non-treated (NT) conditions and #p < 0.05 and ##p < 0.01 for nCeO2 compared to amsCeO2
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has been found to be upregulated following pulmonary
instillation of nCeO2 in rats [10], and is a known pro-
fibrotic signal. As such, the TGFβ receptor inhibitor
SB431542 was used, and fibroblast cells were incubated
with this inhibitor for 3 h prior to the addition of
nanoparticles. Following suppression of TGFβ signaling,
nCeO2-induced cell proliferation was diminished to
levels resembling controls (Fig. 6a). Similarly, analysis of
fibrotic nodule formation revealed that inhibition of
TGFβ signaling attenuated nCeO2-induced fibrogenicity
Fig. 3 nCeO2 induces collagen I production from NHLFs, a hallmark of fibrosis, while amsCeO2 does not. Primary human lung fibroblasts were
treated with the indicated nanoparticle for 48 h. Western blot analysis with corresponding densitometry (a) and fluorescence microscopy
(b) revealed a nCeO2-induced increase in collagen I production, while the amorphous silica coating of nCeO2 attenuated this observed effect on
collagen production. SWCNTs and TGFβ (1 ng/mL) also significantly increased the expression of collagen I, as expected. (c) Alpha-smooth muscle
actin staining of NHLFs that had been treated for 48 h with 0.2 μg/cm2 of the indicated nanoparticle demonstrated that nCeO2, as well as the
Sigma CeO2, SWCNTs, and TGFβ, increased expression of this myofibroblast marker. In contrast, the amsCeO2, as well as the aSiO2 control,
expressed levels consistent with non-treated (NT) cells. Statistical significance is indicated as *p < 0.05 compared to NT conditions and #p < 0.05
for nCeO2 compared to amsCeO2
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Fig. 4 (See legend on next page.)
Davidson et al. Particle and Fibre Toxicology  (2016) 13:23 Page 7 of 14
(Fig. 6b). Inhibition of TGFβ signaling also decreased
collagen I production as induced by nCeO2, demon-
strated by decreased collagen I staining of NHLFs
(Fig. 6c) and via western blot analysis (Fig. 6d). Collect-
ively, these results indicate that nCeO2 induces TGFβ
signaling in fibroblast cells that ultimately leads to in-
creased fibrogenicity.
Discussion
Use of nCeO2 is quickly on the rise worldwide, with an in-
creasing number of applications. Additionally, the in-
creased use as a diesel fuel additive is leading to elevated
levels of nCeO2 released in diesel fuel exhaust, further in-
creasing exposure to the general public [5]. Currently, re-
ports of the implications of nCeO2 treatment, both in cell
culture models as well as animal models, tend to be con-
flicting in their determination of whether nCeO2 is haz-
ardous or safe. Indeed, some report the potential efficacy
of this compound as a therapeutic agent based on its anti-
oxidant and anti-inflammatory properties [30–32]. Still
others, such as those discussed within this report, contend
that nCeO2 is a potential hazard due to its observed fibro-
genicity. This discrepancy seems to be based primarily on
the route of exposure, with inhalation being the most haz-
ardous. These results, taken together with reports of
nCeO2-induced pulmonary disease and fibrosis following
inhalation exposure [5, 6, 10, 12], raise public health con-
cerns due to the fact that most current applications of
nCeO2 employed have the ability to generate respirable
particles.
The potential health hazards caused by exposure to
ENMs such as nCeO2 has led to the development of alter-
native engineering methods to create safer materials while
still maintaining the desirable characteristics of the mater-
ial, commonly referred to as “safety-by-design” strategies.
One such method employs a nano-thin layer of amorph-
ous silica to “mask” the outside of the particle, since
amorphous silica is considered to be relatively biologically
inert [16, 33]. One main concern with these types of strat-
egies is that the core material will no longer possess its de-
sired properties once encapsulated. Indeed, in the case of
CeO2, the desirable catalytic properties may not be
retained with an aSiO2 coating; thus, depending on the ap-
plication, this strategy may not always prove fruitful. How-
ever, when considering the observed results obtained in
rat models, that amsCeO2 causes less acute inflammation
and pulmonary cell toxicity as compared to the uncoated
nCeO2, and minimizes markers of fibrosis such as the ac-
cumulation of surfactant in the air space and collagen pro-
duction [9, 17], it seems that this strategy is worth
pursuing when the application would tolerate such coat-
ings. Consistent with this notion, nano-thin aSiO2 coating
(See figure on previous page.)
Fig. 4 nCeO2, but not amsCeO2, directly induces the formation of fibroblastic nodules in NHLFs in a dose dependent manner. Fibroblasts were
plated on poly-L-lysine coated coverslips and treated with the indicated nanoparticle at 0.006 or 0.2 μg/cm2 for 48 h. Cells were then stained for
collagen I and DAPI and fibroblastic nodule formation was determined for each condition as the number of nodules formed per well. (a) Representative
images of nodule formation in response to 0.2 μg/cm2 of the indicated particles. Collagen I expression is shown in green and nuclear stain
(DAPI) in blue. (b) Brightfield images of the fibroblastic nodules (arrows) were used to quantitate the number of nodules formed per well
in response to each of the indicated nanoparticles. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001 compared
to non-treated (NT) conditions and ###p< 0.001 for nCeO2 compared to amsCeO2. (c) Confocal microscopy Z-stack analysis with orthogonal views (upper
panels) of the X-Z plane (right) and Y-Z plane (top). Three dimensional reconstruction was generated (bottom panels) based on the results of the Z-stack
images and demonstrated increased thickness of fibrotic nodule clusters formed in response to nCeO2 and TGFβ as compared to the untreated monolayer
of NHLFs, indicating the mounding of the cells within the nodule
Fig. 5 nCeO2 particles localize within fibroblastic nodules. NHLFs were treated with 0.2 μg/cm2 of the indicated nanoparticle for 48 h. Following the
treatments, cells were fixed, stained, and mounted onto glass, laser cut slides. Enhanced darkfield microscopy using the CytoViva illumination system
revealed that the nanoparticles (bright spots) are localized on and around the fibroblastic nodules, suggesting that the accumulated particles may play
a role in the initiation or formation of the nodules
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Fig. 6 nCeO2 induced cell proliferation and fibroblastic nodule formation are attenuated with chemical inhibition of TGFβ receptor signaling. NHLFs
were treated as indicated for 48 h. Cells receiving the TGFβ receptor inhibitor SB431542 (SB) were treated for 3 h with 1 μM of inhibitor prior to the
addition of the nanoparticles. Chemical inhibition of the TGFβ receptor reversed the nCeO2-induced increase in cell proliferation (a) and fibroblastic
nodule formation (b) at both of the tested nanoparticle doses. (c) Collagen I staining demonstrated that inhibition of the TGFβ receptor decreased the
nCeO2-induced increase in collagen I production from NHLFs. (d) Western blot analysis and corresponding densitometry further confirmed that the SB
inhibitor reversed the nCeO2-induced increase in collagen I production. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001
compared to non-treated (NT) conditions or compared to other treatments as indicated in D; #p < 0.05, ##p < 0.01, and ###p < 0.001 compared to the
same treatment condition without inhibitor
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also demonstrated a protective effect when used to encap-
sulate iron oxide, reducing both toxicity and genotoxic ef-
fects in two different cell types [34]. Collectively these
reports, as well as the results demonstrated herein, valid-
ate this concept of “safety-by-design” for ENMs for further
study and development.
As previously mentioned, current reports focused on
nCeO2 provide conflicting notions regarding the safety or
potential toxicity of this nanoparticle. While some of these
discrepancies can be attributed to the method of exposure,
such as ingestion versus inhalation, others may be more at-
tributable to differences in the toxicological experimental
methods employed (e.g., dosing, timing, dispersion method,
measured outcome). Unfortunately, there is limited data
on actual human exposure concentrations to nCeO2, and
this makes predicting physiologically relevant doses some-
what difficult for experimental investigation. Likewise,
nanoparticles are known to behave differently in various
types of cell culture or dispersion media, often due to ef-
fects like the formation of protein coronas which can alter
the bio-interactions of these particles once delivered to
cells [17, 35, 36]. Several in vitro studies have examined the
potential toxicity of nCeO2, using numerous cell lines and
endpoints, and most have concluded that nCeO2 is rela-
tively non-toxic and does not illicit a strong inflammatory
response [17, 37–40]. On the contrary, when investigated
in vivo, nCeO2 has demonstrated both pro-inflammatory
and pro-fibrogenic properties [8–10, 12, 14, 17, 41], which
seems more consistent with the reported health effects ob-
served in human case studies [6].
These apparent disparities between in vitro and in vivo
results make evaluating the potential hazards of nCeO2
difficult, and highlight the need for further development
of more reliable and consistent in vitro models to study
and predict the fibrogenicity potential of ENMs. This is
especially important when considering the fact that ani-
mal studies can be time-consuming, costly, and limited
in terms of high-throughput potential when screening a
large number and variety of particles. Given the vast
number of ENMs in use and in development, a number
that continues to grow daily, this notion seems more
critical than ever. Furthermore, in vitro cell models are
useful in allowing more in depth analysis of the specific
mechanisms employed by certain cell types as a result of
exposure that cannot be assessed in vivo due to the
complexity of the entire system. These mechanistic de-
tails can provide vital evidence that may be utilized for
the purpose of developing therapeutic and diagnostic
strategies or outcomes. For example, our model allowed
us to utilize the TGFβ inhibitor SB431542 to investigate
the extent to which TGFβ signaling plays a role in
nCeO2-induced fibrogenicity specifically in fibroblast
cells, which we would not have been able to accomplish
in vivo (Fig. 6). In vivo models will always remain a
necessary approach to predict human response and po-
tential disease outcomes, however, development of more
novel, reliable in vitro methods would be extremely ad-
vantageous in helping to identify select agents that
should be fully characterized using in vivo approaches.
In light of these concerns, we sought to develop a reli-
able in vitro model to examine the potential fibrogenicity
of nCeO2 using primary human fibroblasts. These cells
present a desirable cell type for in vitro analysis of nCeO2
since this particle is known to persist in the lung and has
been found in the interstitium [1, 6, 10, 27–29]. Further-
more, in vivo models suggest that the primary negative
outcome of exposure to nCeO2 is fibrosis, which lends to
the notion that fibroblast cells may be the main cell type
involved in the biological response to nCeO2. Thus, we
directly treated primary human fibroblasts with nCeO2 or
amsCeO2 to assess fibrogenicity. Our group has also pre-
viously employed this strategy to evaluate nanomaterials,
specifically carbon nanotubes, and found that this model
consistently correlated with in vivo outcomes [21, 42]. In
the current report, we observed increased markers of
fibrogenicity, cell proliferation, and collagen production
(Figs. 2 and 3) when NHLFs were directly treated with
nCeO2 at physiologically relevant doses that match those
reported in vivo [9, 10, 12]. nCeO2 is relatively insoluble
under typical cell culture conditions [43], indicating that
the effects reported here are likely due to cellular interac-
tions with particulate nCeO2 rather than dissolved cerium.
In addition, we saw a significant increase in the formation
of fibrotic foci when the cells were treated with nCeO2
(Fig. 4). These findings demonstrate that this in vitro
model was able to accurately mimic results obtained using
in vivo models [9, 10, 12, 17]. Similarly, our results accur-
ately portrayed the observed in vivo effects of the nano-
thin amorphous silica coating of nCeO2 when exposed to
the NHLF cells, showing cell proliferation, collagen ex-
pression, and fibrotic nodule formation at levels consistent
with non-treated and negative controls. These results also
further validate the “safety-by-design” approach for fur-
ther development of ENMs.
As mentioned, the higher dose of nCeO2, 0.2 μg/cm
2,
employed in our studies is equivalent, based on body
weight and surface area of the rat lung, to the physiolo-
gically relevant dose that has been used in numerous in
vivo models to initiate fibrosis. Indeed, using this dose
we also observed the correlative fibrogenic potential of
nCeO2 in our in vitro model. Interestingly, the low dose
of 0.006 μg/cm2 used in these studies, which scarcely in-
duces fibrosis in vivo, also induced a significant fibro-
genic effect in our model. These results are noteworthy
since they indicate that even very low levels of exposure
may have the potential to initiate a fibrotic response.
This is especially important in the case of nanomaterials
when considering their bio-persistence. In addition, this
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finding highlights the notion that reliable in vitro models
may be useful in identifying potentially harmful doses of
materials that would be relevant for follow up using in
vivo models. Indeed, it plausible that interstitial fibro-
blasts would be exposed to lower doses of inhaled nano-
particles than other cell types of the lungs following
exposure, due to factors such as clearance as well as
translocation rate into the interstitium.
Conclusions
In summary, the results presented herein demonstrate
that treatment of primary human lung fibroblasts in vitro
is a useful approach for evaluating the potential fibrogeni-
city of nanomaterials that can efficiently represent results
obtained in vivo. Furthermore, our results confirm those
obtained using an in vivo rat model that a nano-thin coat-
ing of amorphous silica on the surface of nCeO2 can suc-
cessfully ameliorate the fibrogenicity of this nanomaterial.
These results not only support the notion that “safety-by-
design” strategies for developing ENMs are useful, but also
demonstrate the utility of the current in vitro model for
testing the fibrogenic potential of respirable nanoparticles.
Methods
Reagents and antibodies
Fibroblast basal medium, growth supplements, and NHLFs
were purchased from Lonza (Walkersville, MD). Human-
derived transforming growth factor beta (TGFβ), as well as
the TGFβ receptor blocker SB431542, was obtained from
R&D Systems, Inc. (Minneapolis, MN). Poly-L-lysine was
purchased from Sigma-Aldrich (St. Louis, MO). The anti-
Collagen I antibody was purchased from Fitzgerald (Acton,
MA), while the alpha tubulin antibody was purchased
from Santa Cruz Biotechnology, Inc. (Dallas, TX). Alexa-
fluor 488-conjugated donkey anti-rabbit secondary anti-
body, alexa-fluor 488-conjugated alpha-smooth muscle
actin (α-SMA) primary antibody, and the beta actin pri-
mary antibody were purchased from Abcam (Cambridge,
MA). ProLong gold antifade with DAPI mountant was ob-
tained from Molecular Probes (Thermo Fisher Scientific,
Waltham, MA).
Particle generation and characterization
Nano-scaled CeO2, amsCeO2, and aSiO2 particles were
generated using the Harvard Versatile Engineered Nano-
material Generation System (VENGES) and characterized
as previously described [17]. Briefly, x-ray diffraction (XRD)
patterns were obtained using a Scintag XDS2000 powder
diffractometer [Cu Kα (λ = 0.154 nm), −40 kV, 40 mA, step-
size = 0.02°]. The crystal size was determined by applying
the Sherrer Shape Equation to the Gaussian fit of the major
diffraction peak. The Brunauer–Emmett–Teller (BET)
powder-specific surface area (SSA) of all samples was mea-
sured by nitrogen adsorption at 77 K (Micromeritics
TriStar; Norcross, GA), after sample degassing for 1 h at
150 °C in nitrogen. BET equivalent primary particle size
was calculated, under a spherical particle assumption, using
dBET = 6000/(ρ × SSA), where ρ is the material density.
Dry nCeO2, amsCeO2, and aSiO2 particle dispersions in
complete fibroblast growth medium (FGM) were prepared
using a protocol developed by the authors [23], in which
the particle-specific critical delivered sonication energy
(DSEcr), hydrodynamic diameter (dH), formed agglomerate
size distribution, polydispersity index (PdI), zeta potential
(ζ), specific conductance (σ), pH, colloidal stability, and ef-
fective density of formed agglomerates are measured [44].
For treatment of cell cultures, particles were suspended in
DI H2O to acquire stock solutions of 0.1 mg/mL. Immedi-
ately prior to use, all particles were dispersed via sonic-
ation and subsequently diluted in FGM to the desired
concentrations. Particles were then briefly vortexed and
slowly added to the cultures.
Dosimetry
Subsequent to particle suspension, preparation, and
characterization, the delivered-to-cell mass was calcu-
lated. Unlike soluble chemicals, colloidal suspensions of
nanoparticles can have altered surface area, agglomerate
formation, and settling rates depending on the suspen-
sion media, which may impact the bio-interactions of
the particles when deposited onto cells in culture. Thus,
dosimetric considerations must be taken into account.
Therefore, the fraction of administered particle mass
that is deposited on the cells as a function of in vitro ex-
posure time (fD) was calculated [22, 44] in order to ac-
curately replicate the in vivo lung deposited doses of
nCeO2 [9, 10, 12]. The fD as a function of in vitro expos-
ure time was calculated using the hybrid Volumetric
Centrifugation Method-In Vivo Sedimentation, Diffusion
and Dosimetry (VCM-ISDD) methodology [22, 44, 45]
developed by the authors. The mean media-formed
volume-weighted agglomerate hydrodynamic diameter
(dH) and the VCM-measured effective density of formed
agglomerates [44] were used as inputs to the VCM-
ISDD fate and transport numerical model in order to es-
timate the fD as a function of time.
Preparation of carbon nanotubes
Single-walled carbon nanotubes (SWCNT; Carbon Nano-
technologies, Inc., Houston, TX) were produced by the
high pressure CO disproportionation (HipCo) technique,
using CO in a continuous-flow gas phase as the carbon
feedstock and Fe (CO)5 as the iron-containing catalyst pre-
cursor. The SWCNTs were subsequently purified by acid
treatment to remove metal contaminants. Nitric acid dis-
solution and inductively coupled plasma-atomic emission
spectrometry (ICP-AES, NMAM #7300) were used to per-
form an elemental analysis of the supplied SWCNTs, and
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indicated that they contained 99 % elemental carbon and
0.23 % iron. The specific surface area was measured at
−196 °C by the nitrogen absorption-desorption technique
(BET) using a SA3100 Surface Area and Pore Size
Analyzer (Beckman Coulter, Fullerton, CA). The surface
area of dry SWCNT was 400 – 1,000 m2/g, and the length
and width of individual (dry) SWCNT was 0.1 – 1 μm and
0.8 – 1.2 nm, respectively.
Dry SWCNTs were prepared for treatment as previously
described and validated [46]. Briefly, particles were sus-
pended in distilled water to acquire stock solutions of
0.1 mg/mL, which were supplemented subsequently with
150 μg/mL of a natural lung surfactant, Survanta (Abbott
Laboratories, Columbus, OH) to aid in their dispersion. All
particles were then dispersed using brief sonication and di-
luted in culture medium to the desired concentration.
Cell culture
NHLFs were obtained from Lonza (Walkersville, MD) and
cultured in FGM, which is composed of Fibroblast Cell
Basal Medium (FBM; Lonza) that contains all recom-
mended growth supplements (FGM™-2 BulletKit™; Lonza).
Cells were cultured and maintained at sub-confluent dens-
ities in a humidified incubator at 37 °C with 5 % CO2. For
each experiment, cells were seeded at density of 2.5 ×104
cells per well in a 24-well plate the day before treatments
were performed.
Immunofluorescence
Cells were seeded at a density of 2.5 × 104 cells per well
onto glass coverslips that had been treated with poly-L-
lysine (0.1 μg/mL), rinsed, and dried. Prior to their
addition to cells, stock solutions of nanoparticles were
sonicated and subsequently diluted in FGM to the de-
sired concentration. Treated fibroblasts were incubated
with nanoparticles for 48 h and were then fixed in 4 %
paraformaldehyde and permeabilized using phosphate
buffered saline containing 0.25 % Triton-X 100. Cells
were then blocked with 2 % normal donkey serum and
incubated with primary antibody raised against collagen
I, followed by fluorescently conjugated secondary anti-
body. Cover glasses were then mounted on glass slides
using ProLong Gold Antifade mountant with DAPI.
Fluorescent and brightfield images were captured using
a Zeiss Axiovert 100 TV inverted microscope (Carl Zeiss
Microscopy, LLC, Thornwood, NY). For CytoViva im-
ages, coverslips were mounted onto laser-cut glass slides
and images were captured using an Olympus BX-51
Microscope equipped with the CytoViva Advanced Dark
field Illumination System (CytoViva, Auburn, AL) and a
100 W quartz-halogen light source.
Alternatively, cells stained for α-SMA were plated into
chamber slides (Nalgene Nunc International, Naperville,
IL) at a density of 1 ×104 cells per well. Stock solutions
of nanoparticles were sonicated and subsequently diluted
in FGM to the desired concentration for cell treatment.
Fibroblasts were incubated with nanoparticles for 48 h
and cells were then fixed with 4 % paraformaldehyde in
PBS solution on ice for 30 min and permeabilized with
2 % Triton-X 100 for 30 min at room temperature. After
washing, cells were blocked with normal rabbit serum for
1 h and then incubated overnight at 4 °C with primary
antibody raised against α-SMA that was conjugated with
alexa-fluor 488. Cells were then washed and mounted
with mounting solution containing DAPI (Vector Labora-
tories, Inc., Burlingame, CA). Images were taken using a
Nikon Ti Eclipse fluorescent microscope.
Cell proliferation determination
Fibroblast cells were prepared, treated, and imaged as de-
scribed for immunofluorescence. Resultant images were
then analyzed for total cell numbers via Image J software
(Bethesda, MD) by counting the total number of DAPI
stained nuclei per 10X field. Four fields were captured per
coverslip in duplicate for each of three independent
replicates.
Immunoblot analysis and collagen I quantification
Following treatment, whole cell lysates were collected
using cell extraction buffer (Life Technologies, Thermo
Fisher Scientific, Waltham, MA) supplemented with
0.1 mM PMSF and a mixture of protease and phosphatase
inhibitors. Cellular debris was removed by high-speed cen-
trifugation and protein concentrations were then deter-
mined in each sample using the Pierce BCA Protein Assay
(Life Technologies, Thermo Fisher Scientific, Waltham,
MA). Samples (25 μg protein/lane) were separated on so-
dium dodecyl sulfate (SDS)-polyacrylamide gels and elec-
trophoretically transferred to nitrocellulose membranes.
The membranes were then analyzed with collagen I,
beta actin, or alpha tubulin primary antibodies, and
bound antibodies were detected using HRP-conjugated
secondary antibodies. Densitometry was performed on
the resulting bands using Image J software (NIH, Be-
thesda, MD) to quantitate the protein concentration in
each sample.
Fibroblastic nodule assay
NHLFs were seeded onto glass coverslips that had been
treated with poly-L-lysine (0.1 μg/mL) at a density of
2.5 ×104 cells per well in a 24 well plate, and allowed to
adhere overnight. Prior to their addition to cells, nano-
particles were sonicated using a cup sonicator and were
diluted in FGM to the desired concentration. For exper-
iments employing the TGFβ inhibitor SB431542, cells
were incubated with 1 μM of the inhibitor for 3 h prior
to addition of the nanoparticles. Fibroblasts were then
incubated with nanoparticles for 48 h and were
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subsequently fixed in 4 % paraformaldehyde and
permeabilized using phosphate buffered saline contain-
ing 0.25 % Triton-X 100. Cells were then blocked with
2 % normal donkey serum and incubated with primary
antibody raised against collagen I, followed by fluores-
cently conjugated secondary antibody. Cover glasses were
then slowly washed and subsequently mounted on glass
slides using ProLong Gold Antifade mountant with
DAPI. Fluorescent and brightfield Images were cap-
tured using a Zeiss Axiovert 100 TV inverted micro-
scope (Carl Zeiss Microscopy, LLC, Thornwood, NY).
Confocal microscopy z-stack images were obtained
using a Zeiss LSM780 confocal microscope. For each
culture, two cover slides were analyzed and counted for
nodule formation and data was pooled from three inde-
pendent replicates.
Statistical analysis
Data represents mean ± SEM from three or more independ-
ent replicates and samples were analyzed using a one-way
ANOVA with Tukey’s post-test for multiple comparisons to
determine significance. Statistical significance is indicated in
each figure as *p < 0.05, **p < 0.01, and ***p < 0.001. All stat-
istical analyses were performed using GraphPad Prism Soft-
ware (La Jolla, CA).
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